Literature DB >> 11173620

Amount and Avidity of IgG Antibodies to Pseudomonas Aeruginosa Exotoxin A Antigen in Cystic Fibrosis Patients.

Janja Polanec1, Jan Patzer, Jacek Grzybowski, Milan Strukelj, Zlatko P Pavelic.   

Abstract

Amount and avidity of serum IgG antibodies to Pseudomonas aeruginosa exotoxin A in sera of 31 patients with cystic fibrosis (CF) was studied. Eight patients had P. aeruginosa isolated from the sputum on multiple occasions, while from 23 patients no P. aeruginosa was isolated. Amount of IgG antibodies to P. aeruginosa exotoxin A were significantly increased in the serum of patients with P. aeruginosa pulmonary colonization (p<0.0001). On the contrary, serum IgG avidity in the colonized and in the non-colonized CF patients was low (<10) and was statistically different when compared to the 30 age-matched healthy controls (p<0.0001). There was no change in IgG avidity in six chronically infected CF patients from whom we obtained serum samples after half a year period (p=0,55).

Entities:  

Year:  1997        PMID: 11173620     DOI: 10.1007/bf02893348

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  21 in total

1.  Toxin inhibitors of protein synthesis: production, purification, and assay of Pseudomonas aeruginosa toxin A.

Authors:  B H Iglewski; J C Sadoff
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

2.  The functional affinities of antibodies of different IgG subclasses to dietary antigens in mothers and their babies.

Authors:  M E Devey; S Beckman; D M Kemeny
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

3.  Phage typing of Pseudomonas aeruginosa: clinical and epidemiologic considerations.

Authors:  R B Lindberg; R L Latta
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

4.  Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients.

Authors:  U Bruderer; S J Cryz; U B Schaad; M Deusinger; J U Que; A B Lang
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

5.  Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.

Authors:  I Eichler; L Joris; Y P Hsu; J Van Wye; R Bram; R Moss
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

6.  Correlation between specific IgG subclass antibodies to Pseudomonas aeruginosa and opsonic activity in serum from patients with cystic fibrosis.

Authors:  T Pressler; E T Jensen; F Espersen; S S Pedersen; N Høiby; C Koch
Journal:  Pediatr Pulmonol       Date:  1994-01

7.  Longitudinal study of antibody response to lipopolysaccharides during chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.

Authors:  A Fomsgaard; N Høiby; G H Shand; R S Conrad; C Galanos
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

8.  Clinical features, survival rate, and prognostic factors in young adults with cystic fibrosis.

Authors:  N N Huang; D V Schidlow; T H Szatrowski; J Palmer; L R Laraya-Cuasay; W Yeung; K Hardy; L Quitell; S Fiel
Journal:  Am J Med       Date:  1987-05       Impact factor: 4.965

9.  Characterization of antibody response to Pseudomonas aeruginosa in patients with wound infections.

Authors:  E A Trafny; J Grzybowski; J Patzer; D Popiel; J Wrembel-Wargocka; D Dzierzanowska; I Zawistowska-Marciniak; K Kobus
Journal:  Microbiol Immunol       Date:  1991       Impact factor: 2.962

10.  Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis.

Authors:  U B Schaad; A B Lang; J Wedgwood; A Ruedeberg; J U Que; E Fürer; S J Cryz
Journal:  Lancet       Date:  1991-11-16       Impact factor: 202.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.